title: The role of emerging therapy in the management of patients with diffuse low grade glioma.
abstract: OBJECTIVE
  What is the role of immunotherapy/tumor vaccines in the treatment of low grade gliomas?
  
  
  METHODS
  Adult patients with newly diagnosed WHO grade 2 astrocytoma, oligo-astroctyoma, or oligodendroglioma.
  
  
  CONCLUSIONS
  There is no evidence to support a recommendation in regards to the efficacy of immunotherapy or tumor vaccines for the treatment of low grade gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess immunotherapies and tumor vaccines for low grade gliomas.
  
  
  OBJECTIVE
  What is the role of nutrition in the treatment of low grade gliomas?
  
  
  METHODS
  Adult patients with newly diagnosed WHO grade 2 astrocytoma, oligo-astroctyoma, or oligodendroglioma.
  
  
  CONCLUSIONS
  There was no evidence to support a recommendation in regard to the efficacy of nutritional therapy for the treatment of low grade gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess the efficacy of nutrition for this target population.
  
  
  OBJECTIVE
  Is there a role for alternative or targeted therapies in the treatment of low grade gliomas?
  
  
  METHODS
  Adult patients with newly diagnosed WHO grade 2 astrocytoma, oligo-astroctyoma, or oligodendroglioma.
  
  
  CONCLUSIONS
  There was no evidence to support a recommendation in regard to the efficacy of targeted or alternative agents for the treatment of low grade gliomas. It is recommended that patients be enrolled in properly designed clinical trials to assess alternative and targeted therapies for this target population.
authors.affiliation: Department of Neurosurgery and Seidman Cancer Center, University Hospitals and Case Comprehensive Cancer Center, 11100 Euclid Avenue, Cleveland, OH, USA. andrew.sloan@uhhospitals.org.
authors.forename: Andrew E
authors.initials: AE
authors.lastname: Sloan
authors.affiliation: University of Pittsburgh, Pittsburgh, PA, USA.
authors.forename: Hideho
authors.initials: H
authors.lastname: Okada
authors.affiliation: Department of Neurosurgery, Kansas University Medical Center, Kansas City, KS, USA.
authors.forename: Timothy C
authors.initials: TC
authors.lastname: Ryken
authors.affiliation: Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA.
authors.forename: Steven N
authors.initials: SN
authors.lastname: Kalkanis
authors.affiliation: Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Olson
mesh_terms: D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D000529:Complementary Therapies / Q000379:methods; D004032:Diet; D019468:Disease Management; D005910:Glioma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D060787:Neoplasm Grading
keywords: Alternative therapies; Anti-angiogenic therapy; Immunotherapy; Low grade glioma; Molecularly targeted therapy; Nutrition